Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Non Operating Income (2019 - 2026)

Summit Therapeutics filings provide 8 years of Non Operating Income readings, the most recent being $5.8 million for Q1 2026.

  • Quarterly Non Operating Income rose 46.98% to $5.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Mar 2026, up 9.29% year-over-year, with the annual reading at $14.8 million for FY2025, 10.99% up from the prior year.
  • Non Operating Income hit $5.8 million in Q1 2026 for Summit Therapeutics, up from $5.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $16.1 million in Q4 2023 and bottomed at -$5.2 million in Q1 2023.
  • Average Non Operating Income over 5 years is $2.5 million, with a median of $2.4 million recorded in 2025.
  • The largest annual shift saw Non Operating Income plummeted 3833.63% in 2022 before it skyrocketed 689.95% in 2024.
  • Summit Therapeutics' Non Operating Income stood at $5.5 million in 2022, then soared by 194.35% to $16.1 million in 2023, then plummeted by 72.55% to $4.4 million in 2024, then surged by 30.16% to $5.8 million in 2025, then grew by 0.61% to $5.8 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Non Operating Income are $5.8 million (Q1 2026), $5.8 million (Q4 2025), and $2.4 million (Q3 2025).